id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-2317-0004,FDA,FDA-2020-P-2317,Response Letter from FDA CDER to Baxter Healthcare Corporation,Other,Response(s),2021-06-08T04:00:00Z,2021,6,2021-06-08T04:00:00Z,,2021-06-08T13:16:37Z,,0,0,0900006484b5ca79
FDA-2020-P-2317-0003,FDA,FDA-2020-P-2317,"Determination That QUELICIN PRESERVATIVE FREE (Succinylcholine Chloride) Injection, 20 Milligrams/Milliliter, 50 Milligrams/Milliliter, and 100 Milligrams/Milliliter, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness",Notice,Determinations,2021-06-07T04:00:00Z,2021,6,2021-06-07T04:00:00Z,,2021-06-07T13:24:23Z,2021-11802,0,0,0900006484b59180
FDA-2020-P-2317-0001,FDA,FDA-2020-P-2317,Citizen Petition from Baxter Healthcare Corporation,Other,Citizen Petition,2020-12-22T05:00:00Z,2020,12,2020-12-22T05:00:00Z,,2024-11-12T23:27:19Z,,1,0,09000064849b07a7
FDA-2020-P-2317-0002,FDA,FDA-2020-P-2317,Acknowledgment Letter from FDA DMS to Baxter Healthcare Corporation,Other,Acknowledgement Letter/Receipt,2020-12-22T05:00:00Z,2020,12,2020-12-22T05:00:00Z,,2020-12-22T20:00:11Z,,0,0,09000064849b07aa